Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis.
Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report.
Multigate Quality Doppler Profiles and Morphological/Hemodynamic Alterations in Multiple Sclerosis Patients.
Daclizumab (anti-CD25) in multiple sclerosis.
Rare variants in the CYP27B1 gene are associated with multiple sclerosis.
Teva announces FDA acceptance of sNDA for a higher concentration dose of COPAXONE® given three times a week
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multipl
Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.
Does interferon Beta-1a impact pure-tone hearing sensitivity among individuals with multiple sclerosis?
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
Fingolimod is a potential novel therapy for multiple sclerosis.
Roche's MabThera approved for two vasculitis indications in UK
Study to evaluate early glatiramer acetate treatment in delaying conversion to CDMS of subjects presenting with CIS (PreCISe)
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Guillain-Barré syndrome: clinical profile and management.
Cutting Edge: Integrin α4 Is Required for Regulatory B Cell Control of Experimental Autoimmune Encephalomyelitis.
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.
Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand.
Sanofi withdraws Campath in US and EU
Santhera to discontinue sale of Catena® in Canada
A complex role of herpes viruses in the disease process of multiple sclerosis.

Pages